Physician profile
Agbor N Egbewatt
NPI 1063521979
$1,068.78
in general payments reported to CMS, 2019-2025
15 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $65.23 · 2021: $130 · 2022: $136 · 2023: $122 · 2024: $167 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $430.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $239.17 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $136.56 | 2020-2025 | Rybelsus, Ozempic |
| Amgen INC. | $45.27 | 2025 | Krystexxa |
| Abbott Laboratories | $38.36 | 2021 | |
| Boston Scientific Corporation | $34.41 | 2025 | Bodyguardian |
| Dexcom, INC. | $23.49 | 2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $19.12 | 2023 | Krystexxa |
| Vbi Vaccine (Delaware) INC. | $18.67 | 2022 | |
| Glaxosmithkline, LLC. | $16.83 | 2019 | |
| Exact Sciences Corporation | $14.99 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $13.84 | 2019 | |
| Aytu Biopharma, INC. | $13.16 | 2020 | |
| Merck Sharp & Dohme LLC | $12.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agbor Egbewatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.